专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

US20210278407A1 IDENTIFICATION, SELECTION AND USE OF HIGH CURATIVE POTENTIAL T CELL EPITOPES 有权
公开(公告)号：US20210278407A1
公开(公告)日：2021-09-09
申请号：US17328465
申请日：2021-05-24
申请人： Verik Bio, Inc.
发明人： Nancy Parenteau , Joseph Laning , Janet Young
IPC分类号： G01N33/569 , A61K39/00 , G01N33/50 , G01N33/574 , A61K35/17 , C07K14/47
摘要： A method for identifying T-cell epitopes which can be used to elicit T cells targeting cells capable of regenerating cancers is disclosed. The method identifies T-cell epitopes with a high curative potential, high potency and high probability of T cell recognition (HP). The method includes: (i) identifying high curative potential tumor protein target i.e., identifying HP-TP; (ii) identifying peptide sequences within the protein sequence of an HP-TP that have a high probability of eliciting T cell killing; and (iii) qualifying the sequence specificity based on the fold difference between the specific target and non-targets. The identified T-cell epitopes include a core sequence of 9 amino acids homologous to a sequence expressed within a qualified HP-TP. The T-cell epitopes can be used in a method for reprograming T cells to selectively attack tumor cells capable of perpetuating a tumor and treating patients, for example, cancer patients.

2. 发明申请

US20190353655A1 IDENTIFICATION, SELECTION AND USE OF HIGH CURATIVE POTENTIAL T CELL EPITOPES 审中-公开
公开(公告)号：US20190353655A1
公开(公告)日：2019-11-21
申请号：US16436344
申请日：2019-06-10
申请人： Verik Bio, Inc.
发明人： Nancy Parenteau , Joseph Laning , Janet Young
IPC分类号： G01N33/569 , A61K39/00 , G01N33/574 , G01N33/50 , A61K35/17 , C07K14/47
摘要： A method for identifying T-cell epitopes which can be used to elicit T cells targeting cells capable of regenerating cancers is disclosed. The method identifies T-cell epitopes with a high curative potential, high potency and high probability of T cell recognition (HP). The method includes: (i) identifying high curative potential tumor protein target i.e., identifying HP-TP; (ii) identifying peptide sequences within the protein sequence of an HP-TP that have a high probability of eliciting T cell killing; and (iii) qualifying the sequence specificity based on the fold difference between the specific target and non-targets. The identified T-cell epitopes include a core sequence of 9 amino acids homologous to a sequence expressed within a qualified HP-TP. The T-cell epitopes can be used in a method for reprograming T cells to selectively attack tumor cells capable of perpetuating a tumor and treating patients, for example, cancer patients.

3. 发明授权

US10317402B2 Identification, selection and use of high curative potential T cell epitopes 有权
公开(公告)号：US10317402B2
公开(公告)日：2019-06-11
申请号：US14958780
申请日：2015-12-03
申请人： Verik Bio, Inc.
发明人： Nancy Parenteau , Joseph Laning , Janet Young
IPC分类号： C07K7/06 , C07K7/00 , A61K39/00 , G01N33/569 , A61K35/17 , C07K14/47 , G01N33/50 , G01N33/574
摘要： A method for identifying T-cell epitopes which can be used to elicit T cells targeting cells capable of regenerating cancers is disclosed. The method identifies T-cell epitopes with a high curative potential, high potency and high probability of T cell recognition (HP). The method includes: (i) identifying high curative potential tumor protein target i.e., identifying HP-TP; (ii) identifying peptide sequences within the protein sequence of an HP-TP that have a high probability of eliciting T cell killing; and (iii) qualifying the sequence specificity based on the fold difference between the specific target and non-targets. The identified T-cell epitopes include a core sequence of 9 amino acids homologous to a sequence expressed within a qualified HP-TP. The T-cell epitopes can be used in a method for reprogramming T cells to selectively attack tumor cells capable of perpetuating a tumor and treating patients, for example, cancer patients.

4. 发明授权

US11016091B2 Identification, selection and use of high curative potential T cell epitopes 有权
公开(公告)号：US11016091B2
公开(公告)日：2021-05-25
申请号：US16436344
申请日：2019-06-10
申请人： Verik Bio, Inc.
发明人： Nancy Parenteau , Joseph Laning , Janet Young
IPC分类号： A61K35/17 , C07K14/47 , G01N33/569 , A61K39/00 , G01N33/50 , G01N33/574
摘要： A method for identifying T-cell epitopes which can be used to elicit T cells targeting cells capable of regenerating cancers is disclosed. The method identifies T-cell epitopes with a high curative potential, high potency and high probability of T cell recognition (HP). The method includes: (i) identifying high curative potential tumor protein target i.e., identifying HP-TP; (ii) identifying peptide sequences within the protein sequence of an HP-TP that have a high probability of eliciting T cell killing; and (iii) qualifying the sequence specificity based on the fold difference between the specific target and non-targets. The identified T-cell epitopes include a core sequence of 9 amino acids homologous to a sequence expressed within a qualified HP-TP. The T-cell epitopes can be used in a method for reprograming T cells to selectively attack tumor cells capable of perpetuating a tumor and treating patients, for example, cancer patients.

5. 发明申请

US20160161486A1 IDENTIFICATION, SELECTION AND USE OF HIGH CURATIVE POTENTIAL T CELL EPITOPES 审中-公开
标题翻译：鉴定，选择和使用高度可溶性T细胞抗原决定簇
公开(公告)号：US20160161486A1
公开(公告)日：2016-06-09
申请号：US14958780
申请日：2015-12-03
申请人： Verik Bio, Inc.
发明人： Nancy Parenteau , Joseph Laning , Janet Young
IPC分类号： G01N33/569 , C07K14/47 , A61K35/17
CPC分类号： G01N33/56972 , A61K35/17 , A61K39/0011 , C07K14/47 , G01N33/5011 , G01N33/505 , G01N33/574 , G01N2333/912 , G01N2333/96433
摘要： A method for identifying T-cell epitopes which can be used to elicit T cells targeting cells capable of regenerating cancers is disclosed. The method identifies T-cell epitopes with a high curative potential, high potency and high probability of T cell recognition (HP). The method includes: (i) identifying high curative potential tumor protein target i.e., identifying HP-TP; (ii) identifying peptide sequences within the protein sequence of an HP-TP that have a high probability of eliciting T cell killing; and (iii) qualifying the sequence specificity based on the fold difference between the specific target and non-targets. The identified T-cell epitopes include a core sequence of 9 amino acids homologous to a sequence expressed within a qualified HP-TP. The T-cell epitopes can be used in a method for reprogramming T cells to selectively attack tumor cells capable of perpetuating a tumor and treating patients, for example, cancer patients.
摘要翻译：公开了一种鉴定T细胞表位的方法，该方法可用于引发能够再生癌症的靶向细胞的T细胞。该方法鉴定出具有高疗效，高效率和高T细胞识别概率（HP）的T细胞表位。该方法包括：（i）识别高疗效潜在的肿瘤蛋白靶标，即鉴定HP-TP; （ii）鉴定具有诱发T细胞杀伤的可能性高的HP-TP的蛋白质序列内的肽序列; 和（iii）基于特定靶标和非靶标之间的折叠差异来确定序列特异性。所鉴定的T细胞表位包括与合格的HP-TP中表达的序列同源的9个氨基酸的核心序列。 T细胞表位可用于重编程T细胞以选择性攻击能够使肿瘤永久化并治疗患者例如癌症患者的肿瘤细胞的方法。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式